BNP Paribas Arbitrage SA lowered its position in CryoPort Inc (NASDAQ:CYRX) by 46.6% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,057 shares of the consumer goods maker’s stock after selling 2,673 shares during the period. BNP Paribas Arbitrage SA’s holdings in CryoPort were worth $56,000 as of its most recent filing with the Securities & Exchange Commission.
A number of other hedge funds and other institutional investors have also recently modified their holdings of the stock. Cortina Asset Management LLC purchased a new stake in CryoPort in the second quarter valued at approximately $5,723,000. Taylor Wealth Management Partners boosted its position in CryoPort by 0.7% in the second quarter. Taylor Wealth Management Partners now owns 299,830 shares of the consumer goods maker’s stock valued at $5,493,000 after buying an additional 2,050 shares during the last quarter. Taylor Frigon Capital Management LLC boosted its position in CryoPort by 2.5% in the 2nd quarter. Taylor Frigon Capital Management LLC now owns 204,799 shares of the consumer goods maker’s stock worth $3,751,000 after purchasing an additional 4,954 shares in the last quarter. Victory Capital Management Inc. boosted its position in CryoPort by 25.8% in the 1st quarter. Victory Capital Management Inc. now owns 188,200 shares of the consumer goods maker’s stock worth $2,432,000 after purchasing an additional 38,600 shares in the last quarter. Finally, Handelsbanken Fonder AB purchased a new stake in CryoPort in the 2nd quarter worth approximately $2,933,000. Hedge funds and other institutional investors own 60.92% of the company’s stock.
CYRX has been the topic of several recent research reports. Leerink Swann initiated coverage on CryoPort in a research report on Monday, July 15th. They issued a “buy” rating and a $24.00 price objective on the stock. BidaskClub lowered CryoPort from a “buy” rating to a “hold” rating in a research report on Wednesday, August 28th. Needham & Company LLC started coverage on CryoPort in a research note on Monday, July 1st. They set a “buy” rating and a $22.00 target price for the company. Svb Leerink reaffirmed an “outperform” rating on shares of CryoPort in a research note on Monday, July 15th. Finally, B. Riley set a $26.00 target price on CryoPort and gave the stock a “buy” rating in a research note on Friday, July 19th. One investment analyst has rated the stock with a hold rating, four have given a buy rating and one has given a strong buy rating to the company’s stock. CryoPort has an average rating of “Buy” and an average price target of $24.00.
NASDAQ CYRX traded down $1.43 during mid-day trading on Friday, hitting $17.85. The stock had a trading volume of 26,300 shares, compared to its average volume of 612,370. The firm’s 50 day moving average is $21.48 and its 200 day moving average is $16.99. CryoPort Inc has a twelve month low of $8.28 and a twelve month high of $25.02. The company has a debt-to-equity ratio of 0.17, a current ratio of 17.73 and a quick ratio of 17.68. The stock has a market capitalization of $641.03 million, a price-to-earnings ratio of -58.10 and a beta of 0.88.
CryoPort (NASDAQ:CYRX) last posted its quarterly earnings data on Thursday, August 8th. The consumer goods maker reported ($0.08) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.08). CryoPort had a negative return on equity of 17.32% and a negative net margin of 35.71%. The firm had revenue of $8.46 million during the quarter, compared to the consensus estimate of $7.94 million. During the same period in the prior year, the company earned ($0.09) EPS. The firm’s revenue was up 82.7% compared to the same quarter last year. As a group, equities research analysts expect that CryoPort Inc will post -0.3 earnings per share for the current year.
CryoPort, Inc engages in the provision of logistics solutions to the life science industry. It also provides logistics solutions for biologic materials such as immunotherapies, stem cells, CAR-T cells, and reproductive cells for clients worldwide, including points-of-care, clinical research organizations central laboratories, biopharmaceuticals, contract manufacturing, health centers, and university researchers.
Further Reading: What is an Initial Coin Offering (ICO)?
Receive News & Ratings for CryoPort Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for CryoPort and related companies with MarketBeat.com’s FREE daily email newsletter.